BioCatalystWatch
MNOVWorkspace / MNOV / OverviewCompany library
Price
Market cap
Next catalystEntire-study LPLV expected in March 2027MN-166 (ibudilast) — ALS studies · Study completionCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

MN-166 (ibudilast)

Small molecule

MIF × PDE3 × PDE4 × PDE10 × PDE11 × TLR4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

MN-166 (ibudilast)

Small molecule

MIF × PDE3 × PDE4 × PDE10 × PDE11 × TLR4

PreINDP1P2P3FilingApproved

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

MN-166 (ibudilast)

Small molecule

MIF × PDE3 × PDE4 × PDE10 × PDE11 × TLR4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

MN-166 (ibudilast)

Small molecule

MIF × PDE3 × PDE4 × PDE10 × PDE11 × TLR4

PreINDP1P2P3FilingApproved

Other pipelines

Small molecule

Leukotriene receptor × 5-LO × PDE3 × PDE4

PreINDP1P2P3FilingApproved

Small molecule

Leukotriene receptor × 5-LO × PDE3 × PDE4

MN-166 (ibudilast)

Small molecule

MIF × PDE3 × PDE4 × PDE10 × PDE11 × TLR4

PreINDP1P2P3FilingApproved
MN-166 (ibudilast)

Small molecule

MIF × PDE3 × PDE4 × PDE10 × PDE11 × TLR4

MN-166 (ibudilast)

Small molecule

MIF × PDE3 × PDE4 × PDE10 × PDE11 × TLR4

MN-166 (ibudilast)

Small molecule

MIF × PDE3 × PDE4 × PDE10 × PDE11 × TLR4

PreINDP1P2P3FilingApproved

Partner / License out

History / paused

β2-adrenergic receptor × β1-adrenergic receptor

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

MNOV PR & News

PR & News

MNOV SEC archive